Cargando…
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience
PURPOSE: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. METHODS/PATIENTS: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418086/ https://www.ncbi.nlm.nih.gov/pubmed/35739349 http://dx.doi.org/10.1007/s12094-022-02844-5 |
| _version_ | 1784776869725339648 |
|---|---|
| author | Francolini, Giulio Campi, Riccardo Di Cataldo, Vanessa Detti, Beatrice Loi, Mauro Triggiani, Luca La Mattina, Salvatore Borghetti, Paolo Magrini, Stefano Maria Nicosia, Luca Alongi, Filippo Ghirardelli, Paolo Vavassori, Vittorio Allegra, Andrea Gaetano Aquilano, Michele Scoccimarro, Erika Peruzzi, Anna Pastina, Pierpaolo Visani, Luca Desideri, Isacco Serni, Sergio Meattini, Icro Livi, Lorenzo |
| author_facet | Francolini, Giulio Campi, Riccardo Di Cataldo, Vanessa Detti, Beatrice Loi, Mauro Triggiani, Luca La Mattina, Salvatore Borghetti, Paolo Magrini, Stefano Maria Nicosia, Luca Alongi, Filippo Ghirardelli, Paolo Vavassori, Vittorio Allegra, Andrea Gaetano Aquilano, Michele Scoccimarro, Erika Peruzzi, Anna Pastina, Pierpaolo Visani, Luca Desideri, Isacco Serni, Sergio Meattini, Icro Livi, Lorenzo |
| author_sort | Francolini, Giulio |
| collection | PubMed |
| description | PURPOSE: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. METHODS/PATIENTS: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. RESULTS: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). CONCLUSION: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT. |
| format | Online Article Text |
| id | pubmed-9418086 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94180862022-08-28 Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience Francolini, Giulio Campi, Riccardo Di Cataldo, Vanessa Detti, Beatrice Loi, Mauro Triggiani, Luca La Mattina, Salvatore Borghetti, Paolo Magrini, Stefano Maria Nicosia, Luca Alongi, Filippo Ghirardelli, Paolo Vavassori, Vittorio Allegra, Andrea Gaetano Aquilano, Michele Scoccimarro, Erika Peruzzi, Anna Pastina, Pierpaolo Visani, Luca Desideri, Isacco Serni, Sergio Meattini, Icro Livi, Lorenzo Clin Transl Oncol Brief Research Article PURPOSE: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab. METHODS/PATIENTS: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered. RESULTS: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6–7.5, p = 0.0012 and HR 2.8, 95% CI 0.99–8.07, p = 0.05, respectively). CONCLUSION: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT. Springer International Publishing 2022-06-23 2022 /pmc/articles/PMC9418086/ /pubmed/35739349 http://dx.doi.org/10.1007/s12094-022-02844-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Brief Research Article Francolini, Giulio Campi, Riccardo Di Cataldo, Vanessa Detti, Beatrice Loi, Mauro Triggiani, Luca La Mattina, Salvatore Borghetti, Paolo Magrini, Stefano Maria Nicosia, Luca Alongi, Filippo Ghirardelli, Paolo Vavassori, Vittorio Allegra, Andrea Gaetano Aquilano, Michele Scoccimarro, Erika Peruzzi, Anna Pastina, Pierpaolo Visani, Luca Desideri, Isacco Serni, Sergio Meattini, Icro Livi, Lorenzo Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title | Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title_full | Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title_fullStr | Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title_full_unstemmed | Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title_short | Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| title_sort | impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience |
| topic | Brief Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418086/ https://www.ncbi.nlm.nih.gov/pubmed/35739349 http://dx.doi.org/10.1007/s12094-022-02844-5 |
| work_keys_str_mv | AT francolinigiulio impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT campiriccardo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT dicataldovanessa impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT dettibeatrice impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT loimauro impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT triggianiluca impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT lamattinasalvatore impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT borghettipaolo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT magrinistefanomaria impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT nicosialuca impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT alongifilippo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT ghirardellipaolo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT vavassorivittorio impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT allegraandreagaetano impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT aquilanomichele impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT scoccimarroerika impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT peruzzianna impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT pastinapierpaolo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT visaniluca impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT desideriisacco impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT sernisergio impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT meattiniicro impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience AT livilorenzo impactofstereotacticbodyradiotherapyvspalliativeradiotherapyononcologicoutcomesofpatientswithmetastatickidneycancerconcomitantlytreatedwithimmunecheckpointinhibitorsapreliminarymulticentreexperience |